Delving into the Latest Updates on HY1839 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Colitis, UlcerativeCrohn Disease

Inactive Indication-

Originator Organization

Suzhou Pharmavan Cancer Research Center Co., Ltd.

Active Organization

Suzhou Pharmavan Cancer Research Center Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估HY1839在中国健康受试者中单次及多次给药后的安全性和耐受性。次要目的：评估HY1839在中国健康受试者中单次及多次给药后的药代动力学特征；评价食物对健康受试者单次口服HY1839药代动力学的影响；初步探索HY1839在健康受试者体内代谢的物质平衡。

[Translation]

Primary objective: To evaluate the safety and tolerability of HY1839 after single and multiple administrations in healthy Chinese subjects. Secondary objectives: To evaluate the pharmacokinetic characteristics of HY1839 after single and multiple administrations in healthy Chinese subjects; To evaluate the effect of food on the pharmacokinetics of HY1839 after a single oral administration in healthy subjects; To preliminarily explore the material balance of HY1839 metabolism in healthy subjects.

Start Date-

Sponsor / Collaborator

Suzhou Pharmavan Cancer Research Center Co., Ltd.

100 Clinical Results associated with HY1839

Login to view more data

100 Translational Medicine associated with HY1839

Login to view more data

100 Patents (Medical) associated with HY1839

Login to view more data

100 Deals associated with HY1839

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 1	China	Suzhou Pharmavan Cancer Research Center Co., Ltd.	13 May 2022
Crohn Disease	Phase 1	China	Suzhou Pharmavan Cancer Research Center Co., Ltd.	13 May 2022